Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | APR-246 with azacitidine for p53 mutated MDS and AML

Thomas Cluzeau • 12 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes Azacitidine Eprenetapopt

Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discusses the use of APR-246, a PRIMA-1 analog targeting p53 in combination with azacitidine for TP53 mutated myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Thomas Cluzeau

The potential association of plasma venetoclax level with treatment efficacy in first-line AML
2:08
The potential association of plasma venetoclax level with treatment efficacy in first-line AML
Thomas Cluzeau • 8 Dec 2025
Crenolanib plus salvage chemotherapy in FLT3-mutant R/R AML: results from a randomized trial
2:44
Crenolanib plus salvage chemotherapy in FLT3-mutant R/R AML: results from a randomized trial
Thomas Cluzeau • 8 Dec 2025
iwAL 2025 highlights: resistance mechanisms in AML, novel targets, menin inhibitors & more
21:29
iwAL 2025 highlights: resistance mechanisms in AML, novel targets, menin inhibitors & more
Thomas Cluzeau • 19 Sep 2025
Novel targets, treatments, and combinations in AML
Novel targets, treatments, and combinations in AML
Thomas Cluzeau • 29 Sep 2022

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Thomas Cluzeau • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Thomas Cluzeau • 6 Dec 2025
Beat AML abstracts at ASH 2025: ficlatuzumab sub-study, PRISM score, and the impact of co-mutations
3:16
Beat AML abstracts at ASH 2025: ficlatuzumab sub-study, PRISM score, and the impact of co-mutations
Thomas Cluzeau • 6 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Thomas Cluzeau • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals